Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04551898 · ClinicalTrials.gov registry record · Phase 2
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
A Phase 2 study of Covid19, sponsored by BeiGene.
- Completed
- Registry status
- Phase 2
- Development phase
- 181
- Enrollment target
- 18
- Study locations
NCT04551898 is a Phase 2 study of Covid19 that has completed, run by BeiGene. The registered enrollment target is 181 participants, below the 2,700-participant average among 94 other Covid19 trials with a reported enrollment target (93% lower). The trial reports 18 study locations across 4 states.
The verdict
NCT04551898, a Phase 2 study of Covid19, has completed, sponsored by BeiGene.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 181 participants
- Enrollment target
- 18
- Study locations
Study Summary
The primary objective of this study is to evaluate the efficacy of BGB-DXP593 administered intravenously as a single dose in participants with mild to moderate COVID-19
Conditions Studied
Interventions
- DRUG Placebo
- DRUG BGB-DXP593
Study Locations (18)
Florida
- Btc Network Midland Florida Clinical Research Center - DeLand
- Elixia Clinical Research Collaborative - Hollywood
- Homestead Associates in Research Inc - Miami
- Medical Research Center of Miami Ii, Inc - Miami
- Us Associates in Research - Miami
- Continental Research Network - Miami
- Orlando Health Ufhealth Cancer Center - Orlando
Other
- Hospital Das Clinicas Da Faculdade de Medicina de Botucatu - Botucatu
- Fundacao Universidade de Caxias Do Sul - Caxias do Sul
- Consultoria Medica E Pesquisa Clinica - Sorcaba
- Hospital Cardiologica Aguascalientes - Aguascalientes
- IECSI - Monterrey
- Task Clinical Research Centre - Cape Town
- Langeberg Clinical Trials - Cape Town
Michigan
- Revive Research Institute - Dearborn
- Revival Research Institute Farmington Hills - Sterling Heights
Texas
- Amarillo Center For Clinical Research - Amarillo
- Panamerican Clinical Research Us Headquarters - Brownsville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 181 participants |
| Start Date | 2020-12-02 |
| Est. Completion | 2021-05-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04551898
The ClinicalTrials.gov registry entry for NCT04551898 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 181 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,700-participant average among 94 other Covid19 trials with a reported enrollment target (93% lower). The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Covid19 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04551898 reports 18 study locations spanning 4 distinct geographic areas - top geographies include Florida, Other, Michigan.
Frequently Asked Questions
What is clinical trial NCT04551898 about?
NCT04551898 is a clinical study titled "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)". The primary objective of this study is to evaluate the efficacy of BGB-DXP593 administered intravenously as a single dose in participants with mild to moderate COVID-19
What is the current status of trial NCT04551898?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 181 participants. The study started on 2020-12-02. Estimated completion is 2021-05-25.
What conditions does trial NCT04551898 study?
This clinical trial studies the following conditions: Covid19.
What interventions are being tested in trial NCT04551898?
The interventions under investigation include: Placebo (DRUG), BGB-DXP593 (DRUG).
Who is sponsoring clinical trial NCT04551898?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04551898 being conducted?
This trial has 18 study locations across Florida, Michigan, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Covid19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Imaging Immune Activation in COVID-19
RECRUITING · Phase 2
-
Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure
RECRUITING · Phase 2
-
Defibrotide for the Treatment of Severe COVID-19
RECRUITING · Phase 2
-
SARS-Cov-2 (COVID-19) Nasal Pharyngeal and Oral Pharyngeal Wash (SNOW) Trial
ACTIVE NOT RECRUITING · Phase 2
-
COVID-FISETIN: Pilot in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Inflammation
ACTIVE NOT RECRUITING · Phase 2
-
A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.